ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ)
$0.6538 0.0126 (1.9651%)
Analysed ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) News Sources
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
09-10-2026
yahoo.com
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
09-10-2026
yahoo.com
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
12-10-2026
yahoo.com
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
12-10-2026
yahoo.com
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
14-10-2026
yahoo.com
Here's Why You Should Add ANRO Stock to Your Portfolio Now
14-10-2026
yahoo.com
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
15-10-2026
yahoo.com
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
29-09-2026
yahoo.com
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
29-09-2026
advfn.com
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
29-09-2026
marketbeat.com
What is the current price of ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ)?
The current price of ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) is $0.6538.
ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) since the previous trading day is $0.0126.
ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) since the previous trading day is 1.9651%.
What is the most recent average sentiment score for ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ)?
The most recent average sentiment score for ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ)?
The most recent sentiment for ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ) is .
SEC-8K** Filing Available For ALDEYRA THERAPEUTICS INC (ALDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.